Independent of immune effectors, IFN-γ treatment induced significantly enhanced expression levels of IL32, IL1B, IL8, and CXCL1 in the cells from AD compared to the expression levels in cells from Non-AD donors. Here, IL32 is linked to Alzheimer disease.